Montanova Capital LLC Buys New Shares in Celldex Therapeutics, Inc. $CLDX

Montanova Capital LLC bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 121,297 shares of the biopharmaceutical company's stock, valued at approximately $4,513,000. Montanova Capital LLC owned approximately 0.15% of Celldex Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quantinno Capital Management LP grew its holdings in shares of Celldex Therapeutics by 178.7% during the 1st quarter. Quantinno Capital Management LP now owns 65,744 shares of the biopharmaceutical company's stock worth $2,085,000 after purchasing an additional 42,158 shares in the last quarter. Bank of America Corp DE increased its position in shares of Celldex Therapeutics by 70.8% during the first quarter. Bank of America Corp DE now owns 708,647 shares of the biopharmaceutical company's stock valued at $22,478,000 after purchasing an additional 293,759 shares during the period. First Trust Advisors LP raised its stake in shares of Celldex Therapeutics by 78.7% in the first quarter. First Trust Advisors LP now owns 68,470 shares of the biopharmaceutical company's stock valued at $2,172,000 after purchasing an additional 30,157 shares in the last quarter. Sei Investments Co. acquired a new position in shares of Celldex Therapeutics in the first quarter valued at $1,210,000. Finally, Seven Fleet Capital Management LP bought a new position in Celldex Therapeutics in the first quarter worth $929,000.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CLDX. Guggenheim boosted their price target on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the company a "buy" rating in a report on Monday, July 20th. HC Wainwright reiterated a "buy" rating and set a $42.00 target price on shares of Celldex Therapeutics in a research report on Monday, June 15th. UBS Group upped their target price on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a "buy" rating in a research note on Wednesday, June 10th. Wells Fargo & Company increased their price target on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen upgraded shares of Celldex Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Sunday, July 12th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $56.08.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX opened at $39.63 on Tuesday. The business's fifty day moving average price is $38.64 and its two-hundred day moving average price is $33.43. Celldex Therapeutics, Inc. has a fifty-two week low of $21.71 and a fifty-two week high of $45.14. The stock has a market capitalization of $3.11 billion, a price-to-earnings ratio of -9.11 and a beta of 0.87.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.06) by $0.12. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.73 million. Research analysts expect that Celldex Therapeutics, Inc. will post -4.13 EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company's research platforms leverage novel antibody and vaccine technologies designed to engage the patient's immune system, with a particular emphasis on oncology and neurologic indications. Celldex's pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex's lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source